FDA approves a liquid form of Kamada's AATD drug Glassia

07/5/2010 | Reuters

The FDA approved a liquid version of Glassia, Kamada's intravenous drug for alpha-1 antitrypsin deficiency, a condition that can lead to lung-tissue damage and emphysema. Kamada said it is looking for a partner to develop the treatment for other indications.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC